Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (161-170 of 257) with videos related to

Pageof 26
Sort By:
Dermatology and Therapy|January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge StudyJeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
The British Journal of Dermatology|February 10, 2023
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trialsRichard G Langley, Howard Sofen, Ignacio Dei-Cas, et al.
JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.
Journal of the American Academy of Dermatology|September 20, 2020
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, et al.
RMD Open|April 7, 2025
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studiesPhilip J Mease, Lianne S Gensler, Ana-Maria Orbai, et al.
Dermatology and Therapy|June 27, 2024
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL StudyBernhard Korge, Olivier Vanhooteghem, Charles W Lynde, et al.
Dermatology and Therapy|September 28, 2024
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL StudyBernhard Korge, Olivier Vanhooteghem, Charles W Lynde, et al.
Acta Dermato-Venereologica|June 11, 2016
Psoriasis - The Life Course ApproachMichael Dennis Linder, Stefano Piaserico, Matthias Augustin, et al.
The British Journal of Dermatology|January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trialsMark Lebwohl, Richard B Warren, Howard Sofen, et al.
The Journal of Investigative Dermatology|July 22, 2018
A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for PsoriasisAmy C Foulkes, David S Watson, Daniel F Carr, et al.
Pageof 26

Showing results (161-170 of 257) with videos related to

Sort By:
Pageof 26
Dermatology and Therapy|January 20, 2022
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge StudyJeffrey J Crowley, Richard G Langley, Kenneth B Gordon, et al.
The British Journal of Dermatology|February 10, 2023
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trialsRichard G Langley, Howard Sofen, Ignacio Dei-Cas, et al.
JAMA Dermatology|March 29, 2018
Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIRKayleigh J Mason, Jonathan N W N Barker, Catherine H Smith, et al.
Journal of the American Academy of Dermatology|September 20, 2020
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, et al.
RMD Open|April 7, 2025
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studiesPhilip J Mease, Lianne S Gensler, Ana-Maria Orbai, et al.
Dermatology and Therapy|June 27, 2024
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL StudyBernhard Korge, Olivier Vanhooteghem, Charles W Lynde, et al.
Dermatology and Therapy|September 28, 2024
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL StudyBernhard Korge, Olivier Vanhooteghem, Charles W Lynde, et al.
Acta Dermato-Venereologica|June 11, 2016
Psoriasis - The Life Course ApproachMichael Dennis Linder, Stefano Piaserico, Matthias Augustin, et al.
The British Journal of Dermatology|January 16, 2024
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trialsMark Lebwohl, Richard B Warren, Howard Sofen, et al.
The Journal of Investigative Dermatology|July 22, 2018
A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for PsoriasisAmy C Foulkes, David S Watson, Daniel F Carr, et al.
Pageof 26